TY - JOUR
T1 - Clinical and technical considerations for brain PET imaging for dementia
AU - Alzheimer's Disease Neuroimaging Initiative
AU - Acuff, Shelley N.
AU - Mathotaarachchi, Sulantha
AU - Zukotynski, Katherine
AU - Osborne, Dustin
AU - Subramaniam, Rathan
N1 - Funding Information:
Data collection and sharing for this project were funded by the Alzheimer’s Disease Neuroimaging Initiative (ADNI) (National Institutes of Health grant U01 AG024904) and the Department of Defense ADNI (Department of Defense award W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and generous contributions from the following: AbbVie; Alzheimer’s Association; Alzheimer’s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd. and its affiliated company Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research provide funds to support ADNI clinical sites in Canada. Private-sector contributions are facilitated by the Foundation for the National Institutes of Health (www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer’s Therapeutic Research Institute at the University of Southern California. ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of Southern California. No other potential conflict of interest relevant to this article was reported.
Publisher Copyright:
COPYRIGHT © 2020 by the Society of Nuclear Medicine and Molecular Imaging.
PY - 2020/3/1
Y1 - 2020/3/1
N2 - The number of cases of dementia has dramatically increased over the last decade. Imaging of the brain with PET has been used for many years, but in the past decade the radiopharmaceuticals and technology available for imaging dementia have vastly improved. In recent years, the U.S. Food and Drug Administration has approved 3 PET radiopharmaceuticals for detecting amyloid in brain, and tau PET radiopharmaceuticals are being investigated in clinical trials for use in dementia imaging. This paper will discuss different forms of dementia that can be imaged with PET, review common radiopharmaceuticals used for imaging dementia, and provide technical recommendations for performing the studies.
AB - The number of cases of dementia has dramatically increased over the last decade. Imaging of the brain with PET has been used for many years, but in the past decade the radiopharmaceuticals and technology available for imaging dementia have vastly improved. In recent years, the U.S. Food and Drug Administration has approved 3 PET radiopharmaceuticals for detecting amyloid in brain, and tau PET radiopharmaceuticals are being investigated in clinical trials for use in dementia imaging. This paper will discuss different forms of dementia that can be imaged with PET, review common radiopharmaceuticals used for imaging dementia, and provide technical recommendations for performing the studies.
KW - Amyloid
KW - Brain
KW - PET
KW - Tau
UR - http://www.scopus.com/inward/record.url?scp=85081942975&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85081942975&partnerID=8YFLogxK
U2 - 10.2967/jnmt.118.220087
DO - 10.2967/jnmt.118.220087
M3 - Article
C2 - 31182663
AN - SCOPUS:85081942975
SN - 0091-4916
VL - 48
SP - 5
EP - 8
JO - Journal of nuclear medicine technology
JF - Journal of nuclear medicine technology
IS - 1
ER -